Sunday (28.10.2018)

07:30 – 09:00

Scientific Session Interactive Case Discussion

  • Mark Hertzberg
  • Andrew Lister
  • Stage IV NLPHL

    • Dennis Eichenauer
  • Elderly cHL

    • Joanna Romejko-Jarosinska
  • HIV-positive HL

    • Otavio Baiocchi
  • Progress on anti-PD1 moAb

    • Sven Borchmann

09:15 – 10:15

Scientific Symposium (by Chugai Pharma) Oncology meets Autoimmunity

10:30 – 12:00

Scientific Session Biology & Microenvironment

  • Anke van den Berg
  • Christian Steidl
  • Microenvironment

  • Genotyping of cHL via Liquid Biopsy

12:15 – 13:45

Scientific Symposium (by Takeda Oncology) Optimising patient outcomes in relapsed/refractory HL: Tailoring sequencing and treatment targets

14:00 – 15:30

Scientific Session Early Stages

  • Richard Hoppe
  • John Raemaekers
  • Early-Stage Favorable HL: HD16

    • Andreas Engert
  • BREACH: Randomized Phase II Trial

    • Marc André

15:30 – 16:00

Main Program Poster Walk

16:00 – 17:30

Scientific Symposium (by Bristol-Myers Squibb) Focus on cHL: Current Insights and Future Perspectives

17:45 – 19:15

Scientific Session Survivorship & Patients Perspective

  • Flora van Leeuwen
  • Jan Geissler
  • What Patients Really Want: The Global Lymphoma Patient Survey

    • Johathan Pearce
  • Cognitive Behavioral Therapy for Fatigue in HL

    • Hans Knoop
  • Genetic Susceptibility

    • Lindsay Morton

ISHL11 Preliminary Program

ISHL11 Preliminary Program